A5012973322- Diabetes Management and Research
- Diabetes Treatment and Management
- Pancreatic function and diabetes
- Diabetes Management and Education
- Chronic Disease Management Strategies
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Metabolism, Diabetes, and Cancer
- Diabetes and associated disorders
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Adipose Tissue and Metabolism
- Diet and metabolism studies
- Pharmacology and Obesity Treatment
- Muscle metabolism and nutrition
- Health Systems, Economic Evaluations, Quality of Life
- Chronic Kidney Disease and Diabetes
- Primary Care and Health Outcomes
- Wound Healing and Treatments
- Neuroendocrine Tumor Research Advances
- Bone health and osteoporosis research
- Lipoproteins and Cardiovascular Health
- Liver Disease Diagnosis and Treatment
- Nutrition and Health in Aging
- Diet, Metabolism, and Disease
- Diabetic Foot Ulcer Assessment and Management
- Electrical and Bioimpedance Tomography
Royal North Shore Hospital
2015-2024
The University of Sydney
2015-2024
Northern Sydney Local Health District
2016-2024
Migration Institute of Australia
2018
Steno Diabetes Centers
2017
University of Copenhagen
2017
St Vincent's Hospital
2005
Royal Prince Alfred Hospital
2005
North Shore Hospital
2004
Marymount University
1998
In patients with coronary heart disease and a broad range of cholesterol levels, cholesterol-lowering therapy reduces the risk events, but effects on mortality from overall have remained uncertain.In double-blind, randomized trial, we compared pravastatin (40 mg daily) those placebo over mean follow-up period 6.1 years in 9014 who were 31 to 75 age. The had history myocardial infarction or hospitalization for unstable angina initial plasma total levels 155 271 per deciliter. Both groups...
It is not known whether drugs that block the renin-angiotensin system reduce risk of diabetes and cardiovascular events in patients with impaired glucose tolerance.In this double-blind, randomized clinical trial a 2-by-2 factorial design, we assigned 9306 tolerance established disease or factors to receive valsartan (up 160 mg daily) placebo (and nateglinide placebo) addition lifestyle modification. We then followed for median 5.0 years development (6.5 vital status). studied effects on...
The ability of short-acting insulin secretagogues to reduce the risk diabetes or cardiovascular events in people with impaired glucose tolerance is unknown.In a double-blind, randomized clinical trial, we assigned 9306 participants and either disease factors receive nateglinide (up 60 mg three times daily) placebo, 2-by-2 factorial design valsartan addition participation lifestyle modification program. We followed for median 5.0 years incident (and 6.5 vital status). evaluated effect on...
In most patients with type 1 diabetes, adequate glycemic control is not achieved insulin therapy alone. We evaluated the safety and efficacy of sotagliflozin, an oral inhibitor sodium–glucose cotransporters 2, in combination treatment diabetes.
Insulin degludec/insulin aspart (IDegAsp) is the first combination of a basal insulin with an ultralong duration action, and rapid-acting in single injection. This trial compared IDegAsp biphasic 30 (BIAsp 30) adults type 2 diabetes inadequately controlled once- or twice-daily (OD BID) pre- self-mixed without oral antidiabetic drugs.In this 26-week, randomized, open-label, multinational, treat-to-target trial, participants (mean age 58.7 years, 13 BMI 29.3 kg/m(2), HbA1c 8.4% [68 mmol/mol])...
The aim of this study was to determine the prevalence and extent glycemic excursions (hypo- hyperglycemic) in elderly patients with well-controlled type 2 diabetes using a Continuous Glucose Monitor System (CGMS) (Medtronic MiniMed®). Elderly (>65 years old) were recruited if their glycosylated hemoglobin (HbA1c) <7.5% oral hypoglycemic therapy included sulfonylurea. Patients asked undergo two consecutive 72-h periods continuous glucose monitoring at baseline then again 1 month (total 288...
To assess the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, in patients with type diabetes enrolled CANagliflozin cardioVascular Assessment Study (CANVAS) who were on an incretin mimetic [dipeptidyl peptidase-4 (DPP-4) inhibitor or glucagon-like peptide-1 (GLP-1) receptor agonist].CANVAS is double-blind, placebo-controlled study that randomized participants to canagliflozin 100 300 mg placebo added routine therapy. The present post hoc analysis...
How to deal with diabetes and COVID-19 — do we just dial in? The emergence of severe acute respiratory syndrome coronavirus 2 (SARS�CoV�2), the subsequent announcement by World Health Organization a global pandemic, has altered health care across public private sectors. Clearly, disease 2019 (COVID-19) is having huge impact on general practitioners, emergency physicians, intensivists related staff, also impacting day-to-day delivery chronic care. Conditions such as type 1 require regular,...
Abstract Aims To investigate whether long-term glycemic variability (GV) is associated with vascular complication development in type 2 diabetes. Methods In a post hoc FIELD trial analysis, GV was calculated as the standard deviation and coefficient of variation (CV) glycated hemoglobin A1c (HbA1c) fasting plasma glucose. Baseline variables were compared across quartiles on-study by chi square ANOVA. Prospective associations between baseline to 2-year subsequent mortality outcomes analyzed...
To understand the impact of nocturnal and daytime non-severe hypoglycemic events on healthcare systems, work productivity quality life in people with type 1 or 2 diabetes.People diabetes who experienced a event 4 weeks prior to survey were eligible participate and/or hypoglycemia survey. Surveys conducted Argentina, Australia, Brazil, Israel, Mexico South Africa.In total, 300 respondents included nocturnal/daytime surveys (50/participating country/survey). All 68%/62% (nocturnal/daytime)...
Objective To evaluate the extent of patient activation and factors associated with in adults comorbid diabetes chronic kidney disease (CKD). Design A cross-sectional study. Setting Renal/diabetes clinics four tertiary hospitals across two largest states Australia. Study population Adult patients (over 18 years) CKD (estimated glomerular filtration rate <60 mL/min/1.73 m 2 ). Main outcome measures Patients completed Patient Activation Measure, Kidney Disease Quality Life demographic...
OBJECTIVE The American Diabetes Association recommends individuals with type 1 diabetes (T1D) adjust insulin for dietary fat; however, optimal adjustments are not known. This study aimed to determine 1) the relationship between amount and of fat glycemia 2) fat. RESEARCH DESIGN AND METHODS Adults T1D using pump therapy attended research clinic on 9–12 occasions. On first six visits, participants consumed meals containing 45 g carbohydrate 0 g, 20 40 or 60 either saturated, monounsaturated,...
Abstract Aim: To compare glycaemic control and symptomatic hypoglycaemia rates with glargine versus neutral protamine Hagedorn (NPH) in poorly controlled type 1 diabetes patients. Methods: Patients ( n = 125) received preprandial insulin lispro either 62) or NPH 63) at bedtime for 30 weeks a multicentre, randomized, single‐blind (a blinded investigator made titration decisions) study. Basal dosage was titrated to achieve fasting blood glucose (FBG) values <5.5 mmol/L. Results: Baseline...
1. Experimental elevation of plasma non-esterified fatty acid concentrations has been postulated to decrease insulin-stimulated glucose oxidation and storage rates. Possible mechanisms were examined by measuring skeletal muscle glycogen synthase activity content before during hyperinsulinaemia while fasting levels maintained. 2. Fasting maintained in seven healthy male subjects infusion 20% (w/v) Intralipid (1 ml/min) for 120 min a 240 hyperinsulinaemic euglycaemic clamp (100 m-units h-1...
Patients with the metabolic syndrome are more likely to develop type 2 diabetes and may have an increased risk of cardiovascular disease (CVD) events.We aimed establish whether CVD event rates were influenced by as defined World Health Organisation (WHO), National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) International Diabetes Federation (IDF) determine which component(s) (MS) conferred highest in 4900 patients allocated placebo Fenofibrate Intervention Event...
Background People living with diabetes and chronic kidney disease (CKD) experience compromised quality of life. Consequently, it is critical to identify understand factors influencing their health-related life (HRQoL). This study examined associated HRQoL among patients CKD. Methods A cross sectional adults comorbid CKD (eGFR <60 mL/min/1.73m2) recruited from renal clinics four large tertiary referral hospitals in Australia was performed. Each participant completed the Kidney Disease Quality...
Although it is accepted that elevated plasma homocysteine (tHcy) levels occur in end-stage renal disease and type 2 diabetes, the changes with milder dysfunction (e.g., microalbuminuria) are less clearly established. This study explores relationship among tHcy, creatinine clearance (Ccr), albumin excretion rate (AER) a population diabetes.A total of 260 patients diabetes were screened our outpatient clinic during 10 months. Fasting blood samples collected, AER was calculated from an...
NEFAs characteristically are elevated in obese NIDDM patients both the basal state and after insulin. This elevation might aggravate glycemic control by decreasing peripheral glucose disposal (glucose-fatty acid cycle), increasing HGO. Thus, lowering plasma NEFA levels improve carbohydrate metabolism. We therefore measured HGO fuel use (by indirect calorimetry) during last 30 min of a hyperinsulinemic clamp (0.025U.kg-1.h-1) 8 (BMI 34.8 +/- 1.0 kg/m2) complete overnight suppression with...